Evaluation of Diagnostic Significance and Cost Effectiveness of ELISA andIFA for the Diagnosis of Autoimmune Disorders

Background: The presence of antinuclear antibodies (ANA) is a hallmark of autoimmune diseases. AsClinicopathological classification of autoimmune diseases is difficult without laboratory support, laboratory testing isof helps in diagnosis, treatment, prognosis, and prediction of the pathological changes by disease activity. Althoughdifferent tests are available for ANA detection enzyme linked immunosorbent assay (ELISA) is the mainstay ofdiagnosis in most routine laboratories. Indirect immunofluorescence antinuclear antibody test (IFA) though currentlythe “gold standard” it is not widely practiced. Most studies have used Hep2 cells for the detection of autoantibodiesby IFA. However Hep 2000 Ro is superior compared to Hep 2 which lacks capability of detecting someautoantibodies like Ro antibodies. Hence, this study was undertaken to compare the diagnostic value and costeffectiveness of ANA pattern, ELISA with profile testing for patients suspected to have autoimmune disorders.

Results: In the present study we observed high prevalence of autoimmune diseases in females (75.82%).ANA-ELISA in criteria matched cases with respect to ANA-IFA had a low sensitivity (59% versus 80%), higher specificity(84% versus 70%). Statistical analysis of ELISA and IFA with respect to ANA Profile showed a very less sensitivityby ELISA over IFA (51% vs. 78%) and equal specificity (70-72%) in 142 criteria matched cases.

Conclusions: Statistically significant differences between ELISA and IFA infers IFA-ANA is a very appropriatemethod for screening purposes also IFA have capability of finding anti-mitochondrial and other cytoplasmicantibodies, which is not possible with ELISA.

To know more about the article: https://www.longdom.org/archive/imr-volume-14-issue-2-year-2018.html

A standard editorial manager system is utilized for manuscript submission, review, editorial processing and tracking which can be securely accessed by the authors, reviewers and editors for monitoring and tracking the article processing. Manuscripts can be uploaded online at Editorial Tracking System (https://www.longdom.org/submissions/immunome-research.html) or forwarded to the Editorial Office at: immunores@longdom.org

How we work:

• After submission, an acknowledgement with manuscript number is sent to the corresponding author within 7 working days.
• A 21 day window time frame is allotted for peer-review process wherein multiple experts are contacted.
• Author proof is generated within 7 working days after the acceptance decision.

Benefits on Publication:

Open Access: Permanent free access to your article upon publication ensures extensive global reach and readership.

Easy Article Sharing: Our open access enables you to share your article directly with colleagues through email and on social media via a single link, permitting third party reuse with appropriate citation in addition to the retention of content copyright by the author.

Global Marketing: Through promotion in a targeted global email announcement or press release, your article will be seen by thousands of the top-most thought-leaders in your field.

Reprints: Distribute your work to colleagues and at conferences as we provide hard copy color reprints of your article on order.

Media Contact:
Stella M
Journal Manager
Immunome Research
Email: immunores@longdom.or